Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Astellas Appoints New Head of Diversity and Inclusion

Astellas Appoints New Head of Diversity and Inclusion

Astellas Appoints New Head of Diversity and Inclusion

XOSPATA Approval

XOSPATA Approved

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Learn how we're making strides against a life-threatening cancer in the latest Astellas Way Blog from Percival Barretto-Ko, President, Americas

Learn How We're Making Strides Against a Life-threatening Cancer in the Latest Astellas Way Blog from Percival Barretto-Ko, President, Americas Read More

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration Read More

Bringing Light to the Lives of Cancer Patients

Bringing Light to the Lives of Cancer Patients Read More

Astellas Promotes Lei Ding to Vice President, Payer Strategy, Contracts, and Pricing

Astellas Promotes Lei Ding to Vice President, Payer Strategy, Contracts, and Pricing

Astellas Promotes Lei Ding to Vice President, Payer Strategy, Contracts, and Pricing

1

2

3

4

5

6

News

Latest

News / Media

Jan 09, 2019

EVENITY^® SUBCUTANEOUS INJECTION 105mg SYRINGE RECEIVES THE-FIRST-IN-THE-WORLD APPROVAL IN JAPAN FOR THE TREATMENT OF OSTEOPOROSIS AT HIGH RISK OF FRACTURE

News / Media

Jan 08, 2019

Astellas Announces Approval in Japan for the treatment of prostate cancer, Gonax^® for partial changes (addition of dosage and administration) and addition of Gonax^® 240 mg

News / Media

Dec 21, 2018

Astellas Announces Production Subsidiary Astellas Pharma Tech Concludes Share Transfer Agreement with CMIC CMO for Succession of Nishine Plant Business

News / Corporate

Jan 10, 2019

Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization

News / Corporate

Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / Corporate

Dec 14, 2018

Astellas Acquires Potenza Therapeutics